Ed Savory Drives Chemistry at Slingshot Therapeutics
Company - People | May 20, 2025 | Syncona
Slingshot Therapeutics Limited, a Syncona-backed accelerator, has appointed Ed Savory as Head of Chemistry to spearhead its strategic chemistry initiatives. With over 22 years of experience in drug development, including positions at BenevolentAI and Proximagen, Savory's role will involve overseeing chemistry programs, coordinating with CROs, and integrating chemistry into Slingshot's broader research strategy. This strategic hire aims to broaden Slingshot's pipeline and hasten the progress of its therapeutic programs toward clinical development. Savory, with a deep background in asymmetric synthesis, will work alongside academic researchers to advance Slingshot's mission of evolving academic research into clinical solutions. Richard Wooster, CSO of Slingshot, expressed enthusiasm about Savory's addition, citing his extensive experience as invaluable to the company's objectives.
Sectors
- Biotechnology
- Pharmaceutical
- Venture Capital/Private Equity
Geography
- United Kingdom – Slingshot Therapeutics is based in the UK, and Ed Savory has extensive experience in UK biotech companies.
- United States – Ed Savory's previous roles encompass US-based companies, signaling transatlantic drug development collaboration.
- Europe – Slingshot Therapeutics seeks opportunities from European academic institutions.
Industry
- Biotechnology – Slingshot Therapeutics operates within the biotechnology industry, focusing on advancing de-risked therapeutic programs.
- Pharmaceutical – The appointment of Ed Savory, with a background in drug development, highlights the industry's focus on discovering and developing new medicines.
- Venture Capital/Private Equity – Slingshot Therapeutics is a Syncona Accelerator, indicating involvement in venture capital and private equity to fund and support emerging biotech ventures.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Slingshot Therapeutics Limited | Company, Target | Company | A Syncona Accelerator built to advance therapeutic programs from academic research. |
| Syncona | Selling Company, Investor | Company | A leading healthcare investment company supporting Slingshot Therapeutics. |
| Ed Savory | Person of Interest | Person | Newly appointed Head of Chemistry at Slingshot with extensive experience in drug discovery. |
| BenevolentAI | Former Employer | Company | A previous company where Ed Savory served as Senior Vice President of Drug Discovery. |
| Proximagen (Upsher-Smith) | Former Employer | Company | A biotech company where Ed held key roles in research. |
| Richard Wooster | Chief Scientific Officer, Director | Person | CSO of Slingshot Therapeutics, involved in the hiring of Ed Savory. |